Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Orchard Funding warns of impact of GAP product withdrawals

(Sharecast News) - Insurance premium financing specialist Orchard Funding Group updated the market on the guaranteed asset protection (GAP) insurance market on Friday, after a review by the Financial Conduct Authority (FCA). The AIM-traded firm said following the review, several insurers had decided to withdraw their products from the GAP insurance market.

It said GAP insurance is typically offered as an add-on to motor insurance policies, covering the disparity between a vehicle's purchase price and its current market value.

As of 31 December, more than 20% of the group's assets were tied to financing GAP insurance products.

The withdrawal of the insurance offerings was expected to have a material adverse impact on Orchard's financial results for the current financial year.

It said it was actively evaluating the repercussions of the product withdrawals, and it was working on redeploying its assets accordingly.

At 1623 GMT, shares in Orchard Funding Group were down 30.3% at 23p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Yellow Cake NAV slips as uranium values decline
(Sharecast News) - Uranium investor Yellow Cake reported a rise in uranium holdings but a decrease in net asset value due to lower spot prices in its interim results on Tuesday.
Digitalbox FY EBITDA now seen ahead of internal expectations
(Sharecast News) - Digital media business Digtalbox said on Tuesday that it now expects FY24 revenues to be at least £3.5m, while underlying earnings were also seen ahead of management's expectations.
Dianomi expects to record small loss in FY24
(Sharecast News) - Digital advertising business Dianomi warned on Tuesday that it and to record a small loss in FY24 compared to market expectations of a small profit.
Ixico secures new contract with US-based client
(Sharecast News) - Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.